Statements (82)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Molecular_Templates
|
| gptkbp:advocacy |
support initiatives
|
| gptkbp:business_model |
research and development
|
| gptkbp:can_lead_to |
Rucaparib
|
| gptkbp:ceo |
Patrick Mahaffy
|
| gptkbp:clinical_trial |
gptkb:Oncology
ovarian cancer Phase 1 patient recruitment Phase 2 multiple phases regulatory oversight Phase 3 trials ongoing studies published in journals innovative approaches innovative methodologies published data late-stage development study oversight |
| gptkbp:clinical_trial_results_publication |
gptkb:academic_journals
|
| gptkbp:collaboration |
biopharmaceutical companies
|
| gptkbp:collaborations |
academic institutions
collaborative efforts industry partnerships biotech firms |
| gptkbp:community_engagement |
patient advocacy groups
|
| gptkbp:drug_discovery |
research and development
|
| gptkbp:drug_efficacy |
clinical effectiveness
|
| gptkbp:drug_research |
novel compounds
|
| gptkbp:drug_safety |
clinical safety assessments
|
| gptkbp:employees |
over 200
|
| gptkbp:financial_reports |
annual reports
|
| gptkbp:financial_support |
resources for patients
|
| gptkbp:financials |
publicly reported quarterly
|
| gptkbp:focus |
oncology
|
| gptkbp:founded |
gptkb:2009
|
| gptkbp:founder |
Patrick Mahaffy
|
| gptkbp:funding |
grants and investments
|
| gptkbp:grants |
funding opportunities
|
| gptkbp:has_advisory_board |
experts in oncology
|
| gptkbp:head_of_state |
strategic initiatives
|
| gptkbp:headquarters |
gptkb:Boulder,_Colorado
|
| gptkbp:healthcare |
gptkb:2016
development processes new treatment options FDA approved drugs |
| https://www.w3.org/2000/01/rdf-schema#label |
Clovis Oncology
|
| gptkbp:instruction_set |
multiple drug candidates
various stages |
| gptkbp:investment |
financial performance
various venture capital firms quarterly updates public communications |
| gptkbp:investment_focus |
oncology market
|
| gptkbp:market |
oncology trends
oncology sector |
| gptkbp:market_cap |
approximately $300 million
|
| gptkbp:marketing_strategy |
targeted therapies
growth initiatives |
| gptkbp:partnership |
gptkb:Astra_Zeneca
|
| gptkbp:partnerships |
pharmaceutical companies
academic collaborations |
| gptkbp:product |
Rubraca
|
| gptkbp:publications |
peer-reviewed articles
|
| gptkbp:regulatory_compliance |
FDA regulations
FDA submissions |
| gptkbp:research |
cancer biology
|
| gptkbp:research_areas |
gptkb:Oncology
various indications |
| gptkbp:research_focus |
targeted therapies
precision medicine |
| gptkbp:stock_symbol |
CLVS
|
| gptkbp:team |
experienced executives
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
improved survival rates
patient-focused results |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
www.clovisoncology.com
|
| gptkbp:bfsParent |
gptkb:Clovis_AI
|
| gptkbp:bfsLayer |
6
|